The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CELC | +747.9% | +612.14% | +48.02% | +647% |
| S&P | +13.95% | +78.35% | +12.25% | +176% |
Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Focused on targeted cancer therapies, this biotech firm reported a notable insider sale amid a year of extraordinary stock performance.
A top biotech fund just made a bold move while Celcuity trades near record highs—here’s what they might see coming next.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$41.00K | -20.5% |
| Market Cap | $2.10B | 279.6% |
| Market Cap / Employee | $24.09M | 0.0% |
| Employees | 87 | 0.0% |
| Net Income | -$43,804.00K | -47.0% |
| EBITDA | -$42,808.00K | -42.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $74.25M | 489.1% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $320.25M | 230.1% |
| Short Term Debt | $96.00K | -45.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -43.45% | 1.8% |
| Return On Invested Capital | -45.66% | -2.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$44,873.00K | -117.7% |
| Operating Free Cash Flow | -$44,776.00K | -117.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.25 | 3.25 | 5.83 | 43.32 | 1286.89% |
| Price to Tangible Book Value | 3.25 | 3.25 | 5.83 | 43.32 | 1286.89% |
| Enterprise Value to EBITDA | -11.65 | -9.09 | -11.69 | -51.77 | 229.92% |
| Return on Equity | -87.5% | -115.4% | -134.5% | -122.0% | 57.53% |
| Total Debt | $97.95M | $98.71M | $99.42M | $320.35M | 229.59% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
